---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-22-016606"
form_type: "8-K"
ticker: "EDSA"
cik: "0001540159"
company_name: "Edesa Biotech, Inc."
filed_at: "2022-12-16T23:59:59+00:00"
generated_at: "2026-06-21T03:18:48.672992+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Edesa Biotech reports FY2022 net loss $17.55M; cash $7.09M; Phase 2 COVID ARDS positive

## Summary
- Net loss of $17.55M ($1.05 loss per share) vs $13.34M ($1.10) in FY2021.
- Total operating expenses decreased 22% to $18.37M from $23.68M year-over-year.
- Cash and equivalents $7.09M at Sept 30, 2022; subsequent private placement raised ~$3.0M.
- Phase 2 study of EB05 in COVID ARDS showed 84% reduction in risk of death vs placebo at 28 days.
- Phase 2b dermatology study fully enrolled; topline data expected within 4 weeks.

## SEC filing metadata
- accession: 0001654954-22-016606
- form_type: 8-K
- ticker: EDSA
- cik: 0001540159
- company_name: Edesa Biotech, Inc.
- filed_at: 2022-12-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000165495422016606/0001654954-22-016606-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000165495422016606/edsa_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-22-016606
- JSON: https://secwatch.observer/filing/0001654954-22-016606.json
- Plain text: https://secwatch.observer/filing/0001654954-22-016606.txt

## Key facts
- Earnings Releases
  Edesa Biotech, Inc. reported fiscal year ended September 30, 2022 results: net income $17.55 million, or $1.05 per common share, EPS $1.05 per common share.
  - Period: fiscal year ended September 30, 2022
  - Net income: $17.55 million, or $1.05 per common share
  - EPS: $1.05 per common share
  - Result: reported results
  source text: For the fiscal year ended September 30, 2022, Edesa reported a net loss of $17.55 million, or $1.05 per common share, compared to a net loss of $13.34 million, or $1.10 per common share, for the fiscal year ended September 30, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1540159/000165495422016606/0001654954-22-016606-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.